Head and neck(HN)cancer is an endemic disease in Taiwan,China.Locally recurrent HN cancer after full-dose irradia-tion poses a therapeutic challenge,and boron neutron capture therapy(BNCT)may be a solution that could ...Head and neck(HN)cancer is an endemic disease in Taiwan,China.Locally recurrent HN cancer after full-dose irradia-tion poses a therapeutic challenge,and boron neutron capture therapy(BNCT)may be a solution that could provide durable local control with tolerable toxicity.The Tsing-Hua Open Pool Reactor(THOR)at National Tsing-Hua University in Hsin-Chu,provides a high-quality epithermal neutron source for basic and clinical BNCT research.Our first clinical trial,entitled“A phase I/II trial of boron neutron capture therapy for recurrent head and neck cancer at THOR”,was carried out between 2010 and 2013.A total of 17 patients with 23 recurrent HN tumors who had received high-dose photon irradiation were enrolled in the study.The fructose complex of l-boronophenylalanine was used as a boron carrier,and a two-fraction BNCT treatment regimen at 28-day intervals was used for each patient.Toxicity was acceptable,and although the response rate was high(12/17),re-recurrence within or near the radiation site was common.To obtain better local control,another clinical trial entitled“A phase I/II trial of boron neutron capture therapy combined with image-guided intensity-modulated radiotherapy(IG-IMRT)for locally recurrent HN cancer”was initiated in 2014.The first administration of BNCT was performed according to our previous protocol,and IG-IMRT was initiated 28 days after BNCT.As of May 2017,seven patients have been treated with this combination.The treatment-related toxicity was similar to that previously observed with two BNCT applications.Three patients had a complete response,but locoregional recurrence was the major cause of failure despite initially good responses.Future clinical trials combining BNCT with other local or systemic treatments will be carried out for recurrent HN cancer patients at THOR.展开更多
池式研究型反应堆是全球多用途研究堆中的重点类型,因其在安全特性、多用途性和运行维护等方面的突出表现而备受关注。在池式堆中,热功率为1~10 MW的小型研究堆方案设计最为成熟,应用场景最为广泛。为了探索未来池式研究堆堆芯设计及其...池式研究型反应堆是全球多用途研究堆中的重点类型,因其在安全特性、多用途性和运行维护等方面的突出表现而备受关注。在池式堆中,热功率为1~10 MW的小型研究堆方案设计最为成熟,应用场景最为广泛。为了探索未来池式研究堆堆芯设计及其应用场景的发展趋势,首先,根据全球开展RERTR(Reduced Enrichment Research and Test Reactor)低浓化项目并进行堆芯重新设计的小型池式研究堆不同的堆芯方案进行对比,研究分析未来小型池式研究堆堆芯可采用的燃料类型和组件结构,以及目前全球小型池式研究堆的应用情况。其次,总结了小型池式研究堆在燃料类型和堆芯结构两个方面的发展现状,汇总了研究堆各类中子应用场景的技术指标。最终,通过横向对比探究分析推判:未来小型池式研究堆将采用紧凑型堆芯设计,采用高密度的低浓缩铀燃料,以紧凑可移动式小堆芯为基础,以大水池内中子源应用设施为主要发展方向。展开更多
基金supported by“Ministry of science and technology of Taiwan”,China.
文摘Head and neck(HN)cancer is an endemic disease in Taiwan,China.Locally recurrent HN cancer after full-dose irradia-tion poses a therapeutic challenge,and boron neutron capture therapy(BNCT)may be a solution that could provide durable local control with tolerable toxicity.The Tsing-Hua Open Pool Reactor(THOR)at National Tsing-Hua University in Hsin-Chu,provides a high-quality epithermal neutron source for basic and clinical BNCT research.Our first clinical trial,entitled“A phase I/II trial of boron neutron capture therapy for recurrent head and neck cancer at THOR”,was carried out between 2010 and 2013.A total of 17 patients with 23 recurrent HN tumors who had received high-dose photon irradiation were enrolled in the study.The fructose complex of l-boronophenylalanine was used as a boron carrier,and a two-fraction BNCT treatment regimen at 28-day intervals was used for each patient.Toxicity was acceptable,and although the response rate was high(12/17),re-recurrence within or near the radiation site was common.To obtain better local control,another clinical trial entitled“A phase I/II trial of boron neutron capture therapy combined with image-guided intensity-modulated radiotherapy(IG-IMRT)for locally recurrent HN cancer”was initiated in 2014.The first administration of BNCT was performed according to our previous protocol,and IG-IMRT was initiated 28 days after BNCT.As of May 2017,seven patients have been treated with this combination.The treatment-related toxicity was similar to that previously observed with two BNCT applications.Three patients had a complete response,but locoregional recurrence was the major cause of failure despite initially good responses.Future clinical trials combining BNCT with other local or systemic treatments will be carried out for recurrent HN cancer patients at THOR.
文摘池式研究型反应堆是全球多用途研究堆中的重点类型,因其在安全特性、多用途性和运行维护等方面的突出表现而备受关注。在池式堆中,热功率为1~10 MW的小型研究堆方案设计最为成熟,应用场景最为广泛。为了探索未来池式研究堆堆芯设计及其应用场景的发展趋势,首先,根据全球开展RERTR(Reduced Enrichment Research and Test Reactor)低浓化项目并进行堆芯重新设计的小型池式研究堆不同的堆芯方案进行对比,研究分析未来小型池式研究堆堆芯可采用的燃料类型和组件结构,以及目前全球小型池式研究堆的应用情况。其次,总结了小型池式研究堆在燃料类型和堆芯结构两个方面的发展现状,汇总了研究堆各类中子应用场景的技术指标。最终,通过横向对比探究分析推判:未来小型池式研究堆将采用紧凑型堆芯设计,采用高密度的低浓缩铀燃料,以紧凑可移动式小堆芯为基础,以大水池内中子源应用设施为主要发展方向。
